These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31138520)
1. [Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. Bernadach M; Lapeyre M; Dillies AF; Miroir J; Moreau J; Kwiatkowski F; Pham-Dang N; Saroul N; Durando X; Biau J Cancer Radiother; 2019 Jul; 23(4):273-280. PubMed ID: 31138520 [TBL] [Abstract][Full Text] [Related]
2. Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers. Bernadach M; Lapeyre M; Dillies AF; Miroir J; Casile M; Moreau J; Molnar I; Ginzac A; Pham-Dang N; Saroul N; Durando X; Biau J BMC Cancer; 2021 Apr; 21(1):360. PubMed ID: 33827483 [TBL] [Abstract][Full Text] [Related]
3. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560 [TBL] [Abstract][Full Text] [Related]
4. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas. Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580 [TBL] [Abstract][Full Text] [Related]
5. Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer. Nakano K; Seto A; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Takahashi S Anticancer Res; 2019 Aug; 39(8):4337-4342. PubMed ID: 31366527 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854 [TBL] [Abstract][Full Text] [Related]
7. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. Fayette J; Fontaine-Delaruelle C; Ambrun A; Daveau C; Poupart M; Ramade A; Zrounba P; Neidhardt EM; Péron J; Diallo A; Céruse P Oncotarget; 2016 Jun; 7(24):37297-37304. PubMed ID: 27119503 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL; N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012 [TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. Yossi S; Linot B; Peyraga G; Breheret R; Laccourreye L; Capitain O Int J Clin Oncol; 2015 Dec; 20(6):1086-92. PubMed ID: 25931315 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases. Izawa N; Onozawa Y; Hikosaka T; Hamauchi S; Tsushima T; Todaka A; Machida N; Haraguchi Y; Ogawa H; Nishimura T; Nakagawa M; Fuke T; Iida Y; Kamijo T; Onitsuka T; Boku N; Yasui H; Yokota T Int J Clin Oncol; 2015 Jun; 20(3):455-62. PubMed ID: 25248339 [TBL] [Abstract][Full Text] [Related]
13. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ; Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064 [TBL] [Abstract][Full Text] [Related]
14. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck. Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320 [TBL] [Abstract][Full Text] [Related]
17. Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. Driessen CML; Groenewoud JMM; de Boer JP; Gelderblom H; van der Graaf WTA; Prins JB; Kaanders JHAM; van Herpen CML Support Care Cancer; 2018 Apr; 26(4):1233-1242. PubMed ID: 29230548 [TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer. Wang HM; Lin CY; Hsieh CH; Hsu CL; Fan KH; Chang JT; Huang SF; Kang CJ; Liao CT; Ng SH; Yen TC J Formos Med Assoc; 2017 Mar; 116(3):185-192. PubMed ID: 27133181 [TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558 [TBL] [Abstract][Full Text] [Related]
20. [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. Chilimoniuk M; Olszewska E; Maksimowicz T Pol Merkur Lekarski; 2010 Dec; 29(174):357-60. PubMed ID: 21298984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]